Eli Lilly (LLY, Financial) announced promising long-term results for its drug Mirikizumab, marketed as Omvoh, in treating ulcerative colitis (UC) and Crohn's disease. The pharmaceutical company highlighted that Omvoh is the first and only IL23p19 antagonist reported to have sustained efficacy and safety over many years for both conditions, based on two Phase 3 studies targeting moderate to severe UC and Crohn's disease.
In the UC study, 81% of patients maintained long-term clinical remission after three years of treatment, and 82% achieved endoscopic remission. For the Crohn's disease study, 87% achieved clinical remission, while 54% reached endoscopic remission.
Omvoh received approval from the U.S. Food and Drug Administration (FDA) in October 2023 as the first-of-its-kind treatment for adult UC. The drug also holds approval in 44 countries worldwide. Eli Lilly is actively pursuing market applications for Crohn's disease in the U.S., Canada, Europe, Japan, and China, with plans to submit further regulatory documents globally.
Earlier this month, Eli Lilly shared positive data from a one-year Phase 3 study comparing Omvoh to Johnson & Johnson's (JNJ) Stelara in the treatment of Crohn's disease.
